Emerge Bioscience, a Jianyou Subsidiary, Receives FDA Approval for Insulin Aspart Injection
Jianyou Co. , Ltd. announced that its wholly owned subsidiary Emerge Bioscience Pte. has received a Biologics License Application (BLA) approval letter from the U. S. Food and Drug Administration (FDA) for insulin aspart injection. The drug is indicated for improving glycemic control in adult and pediatric patients with diabetes.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 60/100 and 80% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.